Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of early oxytocin treatment in Prader-Willi Syndrome (OT2SUITE)
NCT03081832Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2017
- Primary completion
- May 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label trial of oxytocin in Prader-Willi syndrome (PWS) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Evaluation of communication skills at Day 1. Started Jan 2017; status: completed.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT03081832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081832.